Our study found no significant change in the pooled BNP, which is consistent with the findings of the DEFINE-HF Trial for dapagliflozin and CANVAS for canagliflozin, while the DAPA-HF trial and EMPEROR-Reduced Trial James reported significant reductions in pro-BNP from baseline to the end of follow-up, albeit with low cardiovascular risk outcomes [1,29,30,31]. The gene discussed is NPPB; the disease is hydrops fetalis.